Related Experiment Video
Updated: Jun 16, 2026

Author Spotlight: Understanding and Detecting Environmental Antimicrobial Resistance by Combining Culture-Based Techniques and Genomics
Published on: July 19, 2024
Estimation of anti-diabetes drug metformin in Turkiye using wastewater-based epidemiology
Evsen Yavuz Guzel1, Aslı Atasoy Aydin2, İsmail Ethem Gören2
1Faculty of Fisheries, Department of Basic Science, Cukurova University, Adana, Türkiye.
Abstract:
Metformin is the most commonly used drug for the treatment of type 2 diabetes (T2D), which is dramatically increasing due to factors such as increasing obesity, physical inactivity, and aging of the population. Metformin analysis was carried out in composite wastewater samples seasonally collected from wastewater treatment plants in 10 cities in 2019 and 2020 30 cities in 2021 in Turkiye. Metformin was measured in all wastewater samples, with an average concentration of 97.81 μg/l in 2019, 75.19 μg/l in 2020, and 69.13 μg/l in 2021. This study was utilized to predict metformin usage in different sociodemographic regions in Turkiye using a wastewater-based epidemiology (WBE) approach. As a result of the analysis, the average metformin consumption in Turkiye was estimated to be 22.2 ± 9.6 [1.9-63.8] g/d/1,000 persons (mean ± SD [range]). Furthermore, these estimates were compared with data for time, sociodemographic characteristics, and patient numbers. Assessing the correlation with estimates and the socioeconomic classes of the cities in question revealed that cities with high-income levels had the lowest metformin use rate. Finally, the study provides supporting data aiding the development of public health strategies for decreasing the overall load of T2D across Turkiye.
Related Concept Videos
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Therapeutic Drug Monitoring: Drug Analysis Methods
Oral Hypoglycemic Agents: Biguanides and Glitazones

